Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for July, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- FED Front & Center Again
- Roundtable Top Picks of the Week
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/19: Will Bernanke Clarify Matters Today?
- PFP 6/19: Investors Bold in Wake of the Fed
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/19/2013
| Company Name | Symbol | %Change |
|---|---|---|
| LUMOS NETWOR | LMOS | 5.95% |
| SUPPORTCOM I | SPRT | 4.42% |
| SONIC FOUNDR | SOFO | 4.69% |
| GREEN MOUNTA | GMCR | 3.75% |
| SUMITOMO MIT | SMFG | 3.50% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Sanofi’s (SNY - Analyst Report) subsidiary Genzyme recently announced that it has received approval for the production of Fabrazyme (agalsidase beta) at its Framingham manufacturing facility from the European Medicines Agency (“EMA”).
The approval of the Framingham plant comes as a relief for Genzyme, which has been facing supply problems ever since manufacturing issues cropped up at its Allston Landing plant in the US in June 2009.
The Allston manufacturing facility used to produce Genzyme’s key products -- Cerezyme for patients suffering from Gaucher disease and Fabrazyme for patients suffering from Fabry disease. The production issues led to an acute shortage of Fabrazyme and Cerezyme, which in turn affected Genzyme’s top-line and overall financial performance.
Genzyme plans to use the Framingham manufacturing facility for the production of Fabrazyme, following which the company will use the Allston manufacturing facility, primarily for the production of Cerezyme.
Fabrazyme supplies are expected to return to normal levels during the year.
Our Take
Fabrazyme was one of the leading products at Genzyme. However, due to manufacturing issues, Fabrazyme sales slipped. This opportunity was well used by Shire plc. (SHPGY), which projected its product Replagal as an alternative to Fabrazyme.
In March 2011, Shire presented data that suggested that it was safe for patients suffering from Fabry disease to switch to Replagal from Genzyme’s Fabrazyme. Currently, Replagal has established a solid position in the market and it will be challenging for Fabrazyme to recapture the lost market share.
Our Recommendation
We currently have a Neutral recommendation on Sanofi. The stock carries a Zacks #5 Rank (strong sell rating) in the short run. We expect 2012 earnings to be hit by the loss of US exclusivity on Plavix and Avapro.
While new product launches should make significant revenue contributions in the long term, we expect Sanofi to continue to contain operating costs in order to grow earnings in the face of weakening sales of some of its biggest products. We also expect the company to grow through partnering deals and acquisitions.
Get the full Analyst Report on SNY - FREE